A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab
Sang Kyu Lee, Yong Hee Cho, Pu Hyeon Cha, Jeong Soo Yoon, Eun Ji Ro, Woo Jeong Jeong, Jieun Park, Hyuntae Kim, Tae Il Kim, Do Sik Min, Gyoonhee Han, Kang Yell Choi
Dive into the research topics of 'A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab'. Together they form a unique fingerprint.